• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tuberculosis series 2020.

作者信息

Silva Denise Rossato, Mello Fernanda Carvalho de Queiroz, Migliori Giovanni Battista

机构信息

. Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil.

. Instituto de Doenças do Tórax - IDT - Faculdade de Medicina, Universidade Federal do Rio de Janeiro - UFRJ - Rio de Janeiro (RJ) Brasil.

出版信息

J Bras Pneumol. 2020 Mar 2;46(2):e20200027. doi: 10.36416/1806-3756/e20200027.

DOI:10.36416/1806-3756/e20200027
PMID:32130340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7462710/
Abstract
摘要

相似文献

1
Tuberculosis series 2020.《2020年结核病系列》
J Bras Pneumol. 2020 Mar 2;46(2):e20200027. doi: 10.36416/1806-3756/e20200027.
2
Latent tuberculosis infection, its treatment, and the control and elimination of tuberculosis.
Isr Med Assoc J. 2002 Jan;4(1):31-2.
3
Tuberculosis and human rights.
Int J Tuberc Lung Dis. 2003 Mar;7(3):304; author reply 304.
4
Childhood tuberculosis: ending the neglect.儿童结核病：终结被忽视的状况。
Int J Tuberc Lung Dis. 2002 May;6(5):373-4.
5
[Tuberculosis chemotherapy. Introduction].[结核病化疗。引言]
Rev Prat. 1979 Jun 11;29(33):2621-4.
6
Advances in Tuberculosis: Therapeutics.结核病进展：治疗学
Indian J Pediatr. 2019 Aug;86(8):700-702. doi: 10.1007/s12098-019-03005-3. Epub 2019 Jun 18.
7
Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis.经验性治疗对结核病诊断试验临床试验结果的影响。
Lancet Infect Dis. 2015 Jan;15(1):16-7. doi: 10.1016/S1473-3099(14)71026-6.
8
Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis.经验性治疗对结核病诊断检测临床试验结果的影响。
Lancet Infect Dis. 2015 Jan;15(1):17-8. doi: 10.1016/S1473-3099(14)71049-7.
9
[Therapy in tuberculosis].[结核病的治疗]
Orv Hetil. 2004 Apr 18;145(16):871-3.
10
Tuberculosis in Children.儿童结核病
Pediatr Rev. 2019 Apr;40(4):168-178. doi: 10.1542/pir.2018-0093.

引用本文的文献

1
First Molecular Evidence of Emerging Lophomonas Pathogen Among Patients Suspected of Having Pulmonary Tuberculosis in Mazandaran Province, Northern Iran.伊朗北部马赞达兰省疑似肺结核患者中新兴唇滴虫病原体的首次分子证据。
Acta Parasitol. 2024 Mar;69(1):1041-1045. doi: 10.1007/s11686-023-00729-3. Epub 2023 Dec 18.
2
High Occurrence of Emerged Infection among Patients Suspected of Having Pulmonary Tuberculosis: In-House PCR-Based Evidence.疑似肺结核患者中新发感染的高发生率：基于院内聚合酶链反应的证据
Interdiscip Perspect Infect Dis. 2022 Dec 1;2022:2742164. doi: 10.1155/2022/2742164. eCollection 2022.
3
Panorama of Bacterial Infections Caused by Epidemic Resistant Strains.流行耐药菌株引起的细菌性感染全景图。
Curr Microbiol. 2022 Apr 30;79(6):175. doi: 10.1007/s00284-022-02875-9.
4
The Footprint of Diabetes Mellitus on the Characteristics and Response to Anti-Tuberculous Therapy in Patients with Pulmonary Tuberculosis from Saudi Arabia.糖尿病对沙特阿拉伯肺结核患者抗结核治疗特征及反应的影响
Infect Drug Resist. 2021 Dec 10;14:5303-5312. doi: 10.2147/IDR.S344703. eCollection 2021.
5
The Role of Extracellular Vesicles from Human Macrophages on Host-Pathogen Interaction.人巨噬细胞外囊泡在宿主-病原体相互作用中的作用。
Int J Mol Sci. 2021 Sep 23;22(19):10262. doi: 10.3390/ijms221910262.
6
Solid Lipid Nanoparticles as Formulative Strategy to Increase Oral Permeation of a Molecule Active in Multidrug-Resistant Tuberculosis Management.固体脂质纳米粒作为一种制剂策略，用于提高在耐多药结核病治疗中具有活性的分子的口服渗透性。
Pharmaceutics. 2020 Nov 24;12(12):1132. doi: 10.3390/pharmaceutics12121132.

本文引用的文献

1
Management of multidrug-resistant tuberculosis: main recommendations of the Brazilian guidelines.耐多药结核病的管理：巴西指南的主要建议。
J Bras Pneumol. 2020;46(2):e20190290. doi: 10.36416/1806-3756/e20190290. Epub 2020 May 11.
2
Shortened tuberculosis treatment regimens: what is new?缩短结核病治疗方案：有哪些新进展？
J Bras Pneumol. 2020 Mar 23;46(2):e20200009. doi: 10.36416/1806-3756/e20200009. eCollection 2020.
3
Analysis of the incidence of latent Mycobacterium tuberculosis infection among primary health care professionals in two Brazilian capitals.巴西两个首都的初级卫生保健专业人员中潜伏性结核分枝杆菌感染发病率分析。
J Bras Pneumol. 2020 Mar 2;46(2):e20190201. doi: 10.36416/1806-3756/e20190201.
4
Bacteriological diagnosis of tuberculosis in prison inmates: actions taken by the primary health care teams in prisons.监狱服刑人员结核病的细菌学诊断：监狱基层医疗团队采取的行动
J Bras Pneumol. 2020 Mar 2;46(2):e20190179. doi: 10.36416/1806-3756/e20190179.
5
Association between the radiological presentation and elapsed time for the diagnosis of pulmonary tuberculosis in the emergency department of a university hospital.大学医院急诊科中放射学表现与肺结核诊断时间的关联。
J Bras Pneumol. 2020 Mar 2;46(2):e20180419. doi: 10.36416/1806-3756/e20180419. eCollection 2020.
6
Factors associated with tuberculosis and multidrug-resistant tuberculosis in patients treated at a tertiary referral hospital in the state of Minas Gerais, Brazil.巴西米纳斯吉拉斯州一家三级转诊医院治疗的患者中与肺结核和耐多药肺结核相关的因素。
J Bras Pneumol. 2020 Mar 2;46(2):e20180386. doi: 10.36416/1806-3756/e20180386. eCollection 2020.
7
Spirometry results after treatment for pulmonary tuberculosis: comparison between patients with and without previous lung disease: a multicenter study.肺结核治疗后的肺功能检查结果：有和无既往肺部疾病患者的比较：一项多中心研究。
J Bras Pneumol. 2020 Mar 2;46(2):e20180198. doi: 10.36416/1806-3756/e20180198. eCollection 2020.
8
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.耐药结核病治疗中不良反应监测：第一份全球报告。
Eur Respir J. 2019 Dec 19;54(6). doi: 10.1183/13993003.01522-2019. Print 2019 Dec.
9
Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation.重度结核病及其后遗症的管理：从重症监护到手术与康复
J Bras Pneumol. 2019 Apr 25;45(2):e20180324. doi: 10.1590/1806-3713/e20180324.
10
Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.减少结核病传播：世界卫生组织欧洲区域办事处的共识文件。
Eur Respir J. 2019 Jun 5;53(6). doi: 10.1183/13993003.00391-2019. Print 2019 Jun.